463 related articles for article (PubMed ID: 33743237)
21. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
[TBL] [Abstract][Full Text] [Related]
22. Plasma exchange for Guillain-Barré syndrome.
Raphaël JC; Chevret S; Hughes RA; Annane D
Cochrane Database Syst Rev; 2002; (2):CD001798. PubMed ID: 12076424
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment for pain in Guillain-Barré syndrome.
Liu J; Wang LN; McNicol ED
Cochrane Database Syst Rev; 2013 Oct; (10):CD009950. PubMed ID: 24142399
[TBL] [Abstract][Full Text] [Related]
24. A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method.
Kesici S; Tanyıldız M; Yetimakman F; Bayrakci B
J Child Neurol; 2019 Apr; 34(5):277-283. PubMed ID: 30696330
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
van Doorn PA
Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome.
Hughes RA; Pritchard J; Hadden RD
Cochrane Database Syst Rev; 2011 Mar; (3):CD008630. PubMed ID: 21412923
[TBL] [Abstract][Full Text] [Related]
27. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.
Guo F; Zhang YB
Clin Neurol Neurosurg; 2019 Jun; 181():127-132. PubMed ID: 31039494
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.
Dodel R; Rominger A; Bartenstein P; Barkhof F; Blennow K; Förster S; Winter Y; Bach JP; Popp J; Alferink J; Wiltfang J; Buerger K; Otto M; Antuono P; Jacoby M; Richter R; Stevens J; Melamed I; Goldstein J; Haag S; Wietek S; Farlow M; Jessen F
Lancet Neurol; 2013 Mar; 12(3):233-43. PubMed ID: 23375965
[TBL] [Abstract][Full Text] [Related]
30. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
[TBL] [Abstract][Full Text] [Related]
31. Plasma exchange for Guillain-Barré syndrome.
Raphaël JC; Chevret S; Hughes RA; Annane D
Cochrane Database Syst Rev; 2001; (2):CD001798. PubMed ID: 11406009
[TBL] [Abstract][Full Text] [Related]
32. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.
Lancet; 1993 Mar; 341(8845):586-90. PubMed ID: 8094828
[TBL] [Abstract][Full Text] [Related]
33. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
34. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
Eur J Neurol; 2023 Dec; 30(12):3646-3674. PubMed ID: 37814552
[TBL] [Abstract][Full Text] [Related]
35. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
J Peripher Nerv Syst; 2023 Dec; 28(4):535-563. PubMed ID: 37814551
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.
Fokkink WJR; van Tilburg SJ; de Winter BCM; Sassen SDT; van Doorn PA; Koch BCP; Jacobs BC
Clin Pharmacokinet; 2022 Sep; 61(9):1285-1296. PubMed ID: 35781631
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days.
Raphael JC; Chevret S; Harboun M; Jars-Guincestre MC;
J Neurol Neurosurg Psychiatry; 2001 Aug; 71(2):235-8. PubMed ID: 11459901
[TBL] [Abstract][Full Text] [Related]
39. Role of IV Immunoglobulin in Indian Children With Guillain-Barré Syndrome.
Kalita J; Kumar M; Misra UK
Pediatr Crit Care Med; 2019 Jul; 20(7):652-659. PubMed ID: 30985608
[TBL] [Abstract][Full Text] [Related]
40. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
